<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patient and physician characteristics associated with use of erythropoiesis-stimulating agents in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> patients have not yet been described </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> patients diagnosed from 2001 to 2005 were identified from the Surveillance Epidemiology and End Results-Medicare database </plain></SENT>
<SENT sid="2" pm="."><plain>Multivariate regressions examined the association between patient and physician characteristics and the probability of receiving any erythropoiesis-stimulating agents, and of receiving therapeutic-length (â‰¥ 8 week) treatment episodes </plain></SENT>
<SENT sid="3" pm="."><plain>Among the 6,588 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> patients studied, 65% received erythropoiesis-stimulating agents </plain></SENT>
<SENT sid="4" pm="."><plain>Use of erythropoiesis-stimulating agents was lower for blacks compared to whites (OR 0.78; 95% CI:0.61-0.99), single persons compared to married (OR 0.77; 95% CI:0.62-0.97), Medicaid recipients (OR 0.66; 95% CI:0.55-0.79), and those living in census tracts with lower educational attainment </plain></SENT>
<SENT sid="5" pm="."><plain>Patients who did not consult a hematology-<z:hpo ids='HP_0002664'>oncology</z:hpo> specialist were less likely to receive erythropoiesis-stimulating agents </plain></SENT>
<SENT sid="6" pm="."><plain>Specialist access, financial resources and mobility are key determinants of receipt of erythropoiesis-stimulating agents among <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> patients </plain></SENT>
</text></document>